EUVIMEDEUVIMED entdecken
Kommentar

In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo

Tanvi Gupta, Brooks D Cash

Annals of Internal Medicine · 2024

DOI: 10.7326/j23-0122 ↗

Kurz gefasst

Kommentar in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Tanvi Gupta und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Health Science Center at Houston, Houston, Texas, USA (T.G., B.D.C.). Hauptthemen laut MEDLINE: Irritable Bowel Syndrome.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeHumansAmitriptylineDouble-Blind MethodPrimary Health CareTreatment OutcomeRandomized Controlled Trials as TopicClinical Trials, Phase III as Topic

Substanzen

Amitriptyline

Autor:innen und Institutionen

  • University of Texas Health Science Center at Houston, Houston, Texas, USA (T.G., B.D.C.).

Zitieren

APA

Gupta, T., & Cash, B. D. (2024). In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo. Annals of Internal Medicine. https://doi.org/10.7326/j23-0122

Vancouver

Gupta T, Cash BD. In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo. Annals of Internal Medicine. 2024. doi:10.7326/j23-0122

BibTeX
@article{Gupta2024,
  author = {Gupta, Tanvi and Cash, Brooks D},
  title = {In primary care, second-line IBS therapy with amitriptyline vs. placebo reduced symptoms at 6 mo},
  journal = {Annals of Internal Medicine},
  year = {2024},
  doi = {10.7326/j23-0122}
}
Kostenlos starten →